SCHEMBL14752467

SCHEMBL14752467

CC(=O)c1ccc(-c2cncc(C(=O)NCC(C)(C)c3coc(-c4ccc(F)cc4)n3)c2)s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.46
HDAC8 Q9BY41 2/20 0.46
HDAC4 P56524 2/20 0.46
HDAC7 Q8WUI4 1/20 0.46
HDAC9 Q9UKV0 1/20 0.46
HDAC5 Q9UQL6 1/20 0.46
ULK1 O75385 2/20 0.41
NAMPT P43490 1/20 0.39
CLK1 P49759 1/20 0.36
KDM4E B2RXH2 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2A6 P11509 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
SCN10A Q9Y5Y9 1/20 0.36
IKBKE Q14164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2224975 0.92 HDAC1 (0.47) HDAC1HDAC8HDAC4HDAC7HDAC9
SCHEMBL14752466 0.90 HDAC1 (0.57) HDAC1HDAC8HDAC4HDAC7HDAC9
SCHEMBL2227818 0.82 HDAC1 (0.58) HDAC1HDAC8HDAC4HDAC7HDAC9
SCHEMBL2288946 0.82 HDAC1 (0.56) HDAC1HDAC8HDAC4HDAC7HDAC9
SCHEMBL14752515 0.81 HDAC1 (0.56) HDAC1HDAC8HDAC4HDAC7HDAC9
SCHEMBL14752502 0.80 HDAC1 (0.55) HDAC1HDAC8HDAC4HDAC7HDAC9
SCHEMBL6977120 0.79 HDAC4 (0.71) HDAC1HDAC8HDAC4HDAC7HDAC9
SCHEMBL6976197 0.79 HDAC4 (0.54) HDAC1HDAC8HDAC4HDAC7HDAC9
SCHEMBL14752539 0.77 HDAC1 (0.57) HDAC1HDAC8HDAC4HDAC7HDAC9
SCHEMBL14297309 0.75 HPGD (0.39) HDAC1HDAC8HDAC4HDAC7HDAC9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150038534-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. 2015-02-05 US disclosed
US-8901156-B2 Compounds and methods TEMPERO PHARMACEUTICALS, INC. (US) 2014-12-02 US disclosed
US-20130059883-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. 2013-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038534-A1 COMPOUNDS AND METHODS XDH, LPXN, CCNY HDAC1 640/4885HDAC8 1583/4885HDAC4 1441/4885
US-20130059883-A1 COMPOUNDS AND METHODS XDH, LPXN, CCNY HDAC1 640/4885HDAC8 1583/4885HDAC4 1441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.